http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
-
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
-
Legend Biotech names Carlos Santos as chief financial officer
-
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
-
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
-
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
-
Legend Biotech (LEGN) Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
-
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
-
Legend Biotech (LEGN) announces new data evaluating CARVYKTI
-
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
-
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
-
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
-
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
-
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
-
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
-
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
-
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
-
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
-
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
-
Legend Biotech (LEGN) Appoints Alan Bash as President of CARVYKTI
-
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
-
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
-
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
-
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
-
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"
-
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
-
Legend Biotech (LEGN) Appoints Peter Salovey to its Board
-
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
-
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
-
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
-
Legend Biotech (LEGN) Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial
-
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
-
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
-
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
-
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
-
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
-
NantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive Team
-
Legend Biotech (LEGN) Reports CARVYKTI Approved in EU
-
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
-
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
-
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
-
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
-
Legend Biotech (LEGN) Announces CARVYKTI Receives Recommendation from FDA Committee for Earlier Treatment of Patients with R/R Multiple Myeloma
-
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
-
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
-
Legend Biotech (LEGN) Announces Positive CHMP Opinion for CARVYKTI for Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
